Yanaba, Koichi <br/><br/>
Infliximab and adalimumab, unlike ustekinumab, increase serum KL-6 levels in Japanese patients with psoriasis.  [electronic resource] 

 -  The Journal of dermatology  Aug 2015 
 - 828-9 p.  digital 
<br/><br/> Publication Type: Letter; Comment 
<br/><br/><label>ISSN: </label>1346-8138 
<br/><br/><label>Standard No.: </label>10.1111/1346-8138.12918  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adalimumab<br/>Antibodies, Monoclonal<br/>Antibodies, Monoclonal, Humanized<br/>Humans<br/>Infliximab<br/>Psoriasis<br/>Ustekinumab